The abstract is read at the publisher; the summary is JClub's.
Cotransplanting human islets with human AAT-MSCs in humanized NSG diabetic mice markedly improved glycemic control and prolonged graft survival over 100 days.
- Why it matters: Immune-mediated rejection limits long-term success of islet transplantation in type 1 diabetes, and graft-protective strategies that reduce systemic immunosuppression are needed.
- What they did: Humanized NOD/SCID/IL2Rγ-/- (NSG) mice were reconstituted with human CD34+ cells, diabetes was induced with multiple low-dose STZ doses, and intrahepatic human islet grafts were compared with or without AAT-MSCs while tracking human B- and T-cell responses.
- The result: AAT-MSC cotransplantation reduced serum IgM, linked to lower rejection risk, expanded regulatory B cells, increased IL-10+ cells in grafts, and suppressed Th1, Th17, and cytotoxic T-cell responses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.